In the United States, a rare disease is defined as one that impacts fewer than 200,000 individuals, and in the European Union, a disease is considered rare if it affects fewer than 1 in 2,000 people. Around 7,000 rare diseases have been identified, with Guillain-Barré Syndrome being one of them.
Guillain-Barré Syndrome (GBS) is a condition in which a person's immune system attacks the peripheral nerves. The nerve damage progresses rapidly, causing acute neuromuscular paralysis, and can lead to significant morbidity, disability, and even death. Every year, 22,000 people in the U.S. and Europe are hospitalized with GBS. Currently, there are no approved treatments for this condition in the U.S. Intravenous Immunoglobulin (IVIg) is used off-label to treat GBS.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.